Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team. Keiser PH, et al. Among authors: hernandez je. BMC Infect Dis. 2005 Jan 12;5:2. doi: 10.1186/1471-2334-5-2. BMC Infect Dis. 2005. PMID: 15647105 Free PMC article. Clinical Trial.
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, Gao H, Rosenzweig JR, McClernon DR, Pittman G, Hessenthaler SM, Hernandez JE; NZTA4007 Study Team. Kirkland LR, et al. Among authors: hernandez je. Clin Infect Dis. 2002 Feb 15;34(4):511-8. doi: 10.1086/338400. Epub 2002 Jan 4. Clin Infect Dis. 2002. PMID: 11797179 Clinical Trial.
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team. Nadler JP, et al. Among authors: hernandez je. BMC Infect Dis. 2003 Jun 10;3:10. doi: 10.1186/1471-2334-3-10. BMC Infect Dis. 2003. PMID: 12795812 Free PMC article. Clinical Trial.
Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, Liao Q, Hirani A, Graham N, St Clair M, Hernandez J; NZT40012 Study Team. Ross L, et al. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1107-15. doi: 10.1089/088922201316912718. AIDS Res Hum Retroviruses. 2001. PMID: 11522180
Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
Lonergan JT, McComsey GA, Fisher RL, Shalit P, File TM Jr, Ward DJ, Williams VC, Hessenthaler SM, Lindsey L, Hernandez JE; ESS40010 (TARHEEL) Study Team. Lonergan JT, et al. Among authors: hernandez je. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-42. doi: 10.1097/00126334-200408010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15220700 Clinical Trial.
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE; COL30336 Study Team. Ruane PJ, et al. Among authors: hernandez je. HIV Clin Trials. 2003 Jul-Aug;4(4):231-43. doi: 10.1310/MM9W-BAU0-BT6Q-401B. HIV Clin Trials. 2003. PMID: 12916008 Clinical Trial.
109 results